PL380606A1 - Sposób i preparaty do diagnozowania oraz leczenia stwardnienia rozsianego i polineuropatii zapalno-demielinizacyjnej - Google Patents

Sposób i preparaty do diagnozowania oraz leczenia stwardnienia rozsianego i polineuropatii zapalno-demielinizacyjnej

Info

Publication number
PL380606A1
PL380606A1 PL380606A PL38060606A PL380606A1 PL 380606 A1 PL380606 A1 PL 380606A1 PL 380606 A PL380606 A PL 380606A PL 38060606 A PL38060606 A PL 38060606A PL 380606 A1 PL380606 A1 PL 380606A1
Authority
PL
Poland
Prior art keywords
multiple sclerosis
preparations
polyneuropathy
treatment
demyelinizating
Prior art date
Application number
PL380606A
Other languages
English (en)
Other versions
PL210751B1 (pl
Inventor
Anna Jurewicz
Mariola Matysiak
Krzysztof Selmaj
Original Assignee
Anna Jurewicz
Mariola Matysiak
Krzysztof Selmaj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anna Jurewicz, Mariola Matysiak, Krzysztof Selmaj filed Critical Anna Jurewicz
Priority to PL380606A priority Critical patent/PL210751B1/pl
Priority to PCT/PL2007/000065 priority patent/WO2008033044A1/en
Priority to EP07834893A priority patent/EP2084181B1/en
Priority to AT07834893T priority patent/ATE534663T1/de
Priority to US12/310,893 priority patent/US20100086539A1/en
Publication of PL380606A1 publication Critical patent/PL380606A1/pl
Publication of PL210751B1 publication Critical patent/PL210751B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL380606A 2006-09-12 2006-09-12 Izolowany fragment białka Nogo-A, jego zastosowanie oraz sposób diagnozowania oraz leczenia stwardnienia rozsianego i polineuropatii zapalno-demielinizacyjnej PL210751B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL380606A PL210751B1 (pl) 2006-09-12 2006-09-12 Izolowany fragment białka Nogo-A, jego zastosowanie oraz sposób diagnozowania oraz leczenia stwardnienia rozsianego i polineuropatii zapalno-demielinizacyjnej
PCT/PL2007/000065 WO2008033044A1 (en) 2006-09-12 2007-09-12 A method and preparations for the diagnosis and therapy of multiple sclerosis and immune demyelinating polyneuropathy
EP07834893A EP2084181B1 (en) 2006-09-12 2007-09-12 A method and preparations for the diagnosis and therapy of multiple sclerosis and immune demyelinating polyneuropathy
AT07834893T ATE534663T1 (de) 2006-09-12 2007-09-12 Verfahren und zubereitungen zur diagnose und therapie von multipler sklerose und inflammatorischer demyelinisierender polyneuroradikulitis
US12/310,893 US20100086539A1 (en) 2006-09-12 2007-09-12 Method and preparations for the diagnosis and therapy of multiple sclerosis and immune demyelinating polyneuropathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL380606A PL210751B1 (pl) 2006-09-12 2006-09-12 Izolowany fragment białka Nogo-A, jego zastosowanie oraz sposób diagnozowania oraz leczenia stwardnienia rozsianego i polineuropatii zapalno-demielinizacyjnej

Publications (2)

Publication Number Publication Date
PL380606A1 true PL380606A1 (pl) 2008-03-17
PL210751B1 PL210751B1 (pl) 2012-02-29

Family

ID=38925662

Family Applications (1)

Application Number Title Priority Date Filing Date
PL380606A PL210751B1 (pl) 2006-09-12 2006-09-12 Izolowany fragment białka Nogo-A, jego zastosowanie oraz sposób diagnozowania oraz leczenia stwardnienia rozsianego i polineuropatii zapalno-demielinizacyjnej

Country Status (5)

Country Link
US (1) US20100086539A1 (pl)
EP (1) EP2084181B1 (pl)
AT (1) ATE534663T1 (pl)
PL (1) PL210751B1 (pl)
WO (1) WO2008033044A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1262547A4 (en) * 2000-03-07 2004-12-01 Chiba Prefecture NUCLEIC ACID SEQUENCES WITH INCREASED EXPRESSION IN BENEFIT NEUROBLASTOMA COMPARED WITH UNCRITICAL, HUMAN NEUROBLASTOMA
EP1805209A4 (en) * 2004-10-01 2008-04-02 Univ Yale NOGO-A POLYPEPTIDE FRAGMENTS, VARIANT OF NOGO RECEPTOR-1 POLYPEPTIDES AND USE

Also Published As

Publication number Publication date
EP2084181A1 (en) 2009-08-05
PL210751B1 (pl) 2012-02-29
ATE534663T1 (de) 2011-12-15
US20100086539A1 (en) 2010-04-08
WO2008033044A1 (en) 2008-03-20
EP2084181B1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
BR112012020304A2 (pt) complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit
WO2008026064A3 (en) System and method for modeling and application of interproximal reduction of teeth
WO2008013859A3 (en) Peptide probes for diagnostics and therapeutics
EP3355057A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
PH12012502231A1 (en) Anti-human trop-2 antibody having antitumor activity in vivo
MX337194B (es) Preparados, metodos y estuches utiles para el tratamiento de la tos.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MY161991A (en) Proteasome inhibitors
WO2007084647A8 (en) Visualization of three-dimensional data acquisition
PL1889065T3 (pl) Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
IN2012DN06309A (pl)
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
PL2126049T3 (pl) Przeciwciała przeciwko ludzkiemu wirusowi cytomegalii (HCMV)
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
IN2012DN05186A (pl)
SG170804A1 (en) Pseudomonas aeruginosa outer membrane protein pa0427
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
WO2009027703A3 (en) Identifying organ damage
PL380606A1 (pl) Sposób i preparaty do diagnozowania oraz leczenia stwardnienia rozsianego i polineuropatii zapalno-demielinizacyjnej
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders